Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma

Middleton MR., Schadendorf D., Danson S., Marshall E., Corrie P., Love SB., Mohammed SB., Scudder C., Goff M.

DOI

10.1158/1538-7445.am2017-ct123

Type

Conference paper

Publisher

American Association for Cancer Research

Publication Date

01/07/2017

Permalink Original publication